Sukh Makhnoon1, Robert Yu2, Sonia A Cunningham3, Susan K Peterson1, Sanjay Shete2,3,4. 1. Department of Behavioral Science, UT MD Anderson Cancer Center, Houston, Texas, USA. 2. Department of Biostatistics, UT MD Anderson Cancer Center, Houston, Texas, USA. 3. Department of Epidemiology, UT MD Anderson Cancer Center, Houston, Texas, USA. 4. Division of Cancer Prevention and Population Sciences, UT MD Anderson Cancer Center, Houston, Texas, USA.
Abstract
INTRODUCTION: Discussion of cancer genetic testing with health-care providers (HCPs) is necessary to undergo testing to inform cancer risk assessment and prevention. Given the rapid evolution in genetic testing practice in oncology, we describe the current landscape of population-level cancer genetic testing behaviors. METHODS: A questionnaire including items regarding discussion of cancer genetic testing with HCPs was administered to a nonprobability sample (N = 2,029) of the Texas population. RESULTS: Overall, 11% of respondents discussed cancer genetic testing with HCPs. In multivariable analysis, discussion was significantly related to having a personal history of breast/ovarian/colon cancer (OR = 11.57, 95% CI = 5.34-25.03), personal history of other cancer (OR = 3.18, 95% CI = 1.69-5.97), and health information-seeking behaviors (OR = 1.73, 95% CI = 1.12-2.66). Surprisingly, respondents who believed that inherited predispositions in addition to other modifiable risk factors cause cancer were less likely to discuss genetic testing compared to those who did not believe that inherited cancer predispositions cause cancer (OR = 0.54, 95% CI = 0.36-0.79). DISCUSSION: The high discussion rate may be attributed to increased public awareness of genetic testing and adoption of more inclusive clinical genetic testing guidelines. The findings suggest that efforts to increase public awareness of the utility of genetic testing on personalized cancer risk assessment and cancer prevention are needed.
INTRODUCTION: Discussion of cancer genetic testing with health-care providers (HCPs) is necessary to undergo testing to inform cancer risk assessment and prevention. Given the rapid evolution in genetic testing practice in oncology, we describe the current landscape of population-level cancer genetic testing behaviors. METHODS: A questionnaire including items regarding discussion of cancer genetic testing with HCPs was administered to a nonprobability sample (N = 2,029) of the Texas population. RESULTS: Overall, 11% of respondents discussed cancer genetic testing with HCPs. In multivariable analysis, discussion was significantly related to having a personal history of breast/ovarian/colon cancer (OR = 11.57, 95% CI = 5.34-25.03), personal history of other cancer (OR = 3.18, 95% CI = 1.69-5.97), and health information-seeking behaviors (OR = 1.73, 95% CI = 1.12-2.66). Surprisingly, respondents who believed that inherited predispositions in addition to other modifiable risk factors cause cancer were less likely to discuss genetic testing compared to those who did not believe that inherited cancer predispositions cause cancer (OR = 0.54, 95% CI = 0.36-0.79). DISCUSSION: The high discussion rate may be attributed to increased public awareness of genetic testing and adoption of more inclusive clinical genetic testing guidelines. The findings suggest that efforts to increase public awareness of the utility of genetic testing on personalized cancer risk assessment and cancer prevention are needed.
Authors: Monica L Kasting; Claire C Conley; Aasha I Hoogland; Courtney L Scherr; Jongphil Kim; Ram Thapa; Maija Reblin; Cathy D Meade; M Catherine Lee; Tuya Pal; Gwendolyn P Quinn; Susan T Vadaparampil Journal: Psychooncology Date: 2019-04-11 Impact factor: 3.894
Authors: Joseph A Diaz; Rebecca A Griffith; James J Ng; Steven E Reinert; Peter D Friedmann; Anne W Moulton Journal: J Gen Intern Med Date: 2002-03 Impact factor: 5.128
Authors: Lila J Finney Rutten; Amenah A Agunwamba; Patrick Wilson; Neetu Chawla; Sana Vieux; Danielle Blanch-Hartigan; Neeraj K Arora; Kelly Blake; Bradford W Hesse Journal: J Cancer Educ Date: 2016-06 Impact factor: 2.037
Authors: S Ashida; M Goodman; C Pandya; L M Koehly; C Lachance; J Stafford; K A Kaphingst Journal: Public Health Genomics Date: 2010-09-09 Impact factor: 2.000
Authors: Maija Reblin; Monica L Kasting; Kelli Nam; Courtney L Scherr; Jongphil Kim; Ram Thapa; Cathy D Meade; M Catherine Lee; Tuya Pal; Gwendolyn P Quinn; Susan T Vadaparampil Journal: Breast J Date: 2018-11-28 Impact factor: 2.431
Authors: Susanne B Haga; William T Barry; Rachel Mills; Geoffrey S Ginsburg; Laura Svetkey; Jennifer Sullivan; Huntington F Willard Journal: Genet Test Mol Biomarkers Date: 2013-02-13
Authors: Claire C Conley; Jessica N Rivera Rivera; Eida M Castro-Figueroa; Laura Moreno; Julie Dutil; Jennifer D García; Charité Ricker; Gwendolyn P Quinn; Hatem Soliman; Susan T Vadaparampil Journal: Transl Behav Med Date: 2022-10-07 Impact factor: 3.626